Nurosym by Parasym released a new buyer's guide explaining how to choose non-invasive vagus nerve stimulation devices for anxiety support.
-- Nurosym has announced the publication of a new guide to help people experiencing anxiety make informed decisions when comparing wearable vagus nerve stimulation (VNS) devices. The guide addresses five areas: stimulation pathway, device-specific evidence, safety and regulatory status, comfort, and ease of regular use - criteria that those on the lookout for such devices are largely considering.
For more information, visit: https://nurosym.com/blogs/articles/best-vagus-nerve-stimulation-device-for-anxiety
According to the World Health Organization's September 2026 fact sheet, approximately 470 million people worldwide were living with an anxiety disorder in 2023, representing 5.8% of the global population. With anxiety affecting so many people, Nurosym's guide addresses the importance of understanding device-specific evidence, safety and intended use when evaluating wearable technologies for nervous system support.
The guide addresses this growing need for accessible information by explaining how wearable VNS devices differ in design, stimulation methods and supporting clinical evidence. It encourages readers to verify each device's intended use and regulatory status before purchasing, particularly when comparing products marketed with similar claims about anxiety support and nervous system regulation.
The guide also gives particular attention to stimulation pathways, explaining ear-based stimulation as targeting areas of the outer ear associated with the auricular branch of the vagus nerve. These explanations enable readers to see how this approach differs from stimulation delivered elsewhere on the body.
Within the broader framework, then, the guide positions Nurosym’s own wearable device as one that uses Parasym's AVNT technology to deliver auricular stimulation - highlighting the product for its ability to support nervous system regulation, relaxation, and recovery.
While Nurosym is not intended to treat anxiety disorders, clinical studies involving the company's proprietary neuromodulation technology have reported an average 35% reduction in anxiety symptoms and an 18% improvement in heart rate variability (HRV) in specific study populations.
For those experiencing more than occasional stress, though, the document closes with practical advice: people suffering with persistent or severe anxiety symptoms should speak with a qualified healthcare professional rather than rely solely on wearable devices, which work better as a complementary measure.
Interested parties can find further details about Nurosym at https://nurosym.com/
*Research referenced in this article was conducted using Parasym's neuromodulation technology under research conditions. Findings relate to specific study populations and should not be interpreted as medical claims or guaranteed individual outcomes. Nurosym is a CE-marked medical device in Europe.
Contact Info:
Name: PR Team
Email: Send Email
Organization: Nurosym by Parasym
Address: 18 Saint Cross Street 4th Floor, London, England EC1N 8UN, United Kingdom
Website: https://nurosym.com/
Source: PressCable
Release ID: 89208979
In the event of encountering any errors, concerns, or inconsistencies within the content shared in this press release, we kindly request that you immediately contact us at error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team will be readily accessible to address your feedback within 8 hours and take appropriate measures to rectify any identified issues or facilitate press release takedowns. Ensuring accuracy and reliability are central to our commitment.